Kelman to head new Novartis OTC division

Joins from Johnson & Johnson

Naomi Kelman has been appointed head of the Novartis OTC division, reporting to Joseph Jimenez, chief executive of Novartis.

Kelman joins the Swiss company from Johnson & Johnson where she has held several roles within the consumer and medical device and diagnostic sectors.

Naomi Kelman is the new head of the Novartis OTC division

‘With the upcoming Alcon merger, we have decided to put additional focus on two important businesses which today comprise the Consumer Health Division: OTC and Animal Health, by streamlining and simplifying our decision making process,’ said Jimenez. ‘We look forward to Naomi joining our leadership team – her experience in consumer businesses, combined with her drive for results make her well suited to run our OTC business.’

George Gunn becomes head of Animal Health.

The Novartis OTC and Animal Health businesses will become separate Novartis divisions, in addition to the Pharmaceuticals, Sandoz (generics), Vaccines & Diagnostics Divisions.

Following the completion of the merger of Novartis and Alcon, CIBA Vision and Novartis ophthalmic medicines will be merged into the new Alcon eye care division of Novartis.

Until the close of the Alcon transaction, George Gunn will continue to manage the CIBA Vision business.